School of Nuclear Technology and Chemistry & Biology, Hubei University of Science and Technology, Xianning, 437100, China.
School of Pharmacy, Henan University, Kaifeng, 475001, China.
Bioconjug Chem. 2024 Nov 20;35(11):1687-1698. doi: 10.1021/acs.bioconjchem.4c00414. Epub 2024 Oct 8.
Inflammation within the brain is a hallmark of a wide range of brain diseases. The complex role of inflammatory processes in these conditions suggests that neuroinflammation could be a valuable therapeutic target. While several promising anti-inflammatory agents have been identified, their clinical application in brain diseases is often hampered by the inability to cross the blood-brain barrier (BBB) and reach therapeutically effective concentrations at the pathological sites. This limitation highlights the urgent need for effective BBB-penetrating drug delivery systems designed to target brain inflammation. This review critically examines the recent advances over the past five years in drug delivery strategies aimed at mitigating brain inflammation in Alzheimer's disease and ischemic stroke─two of the leading causes of death and disability worldwide. Additionally, we address the key challenges in this field, offering insights into future directions for targeting neuroinflammation in the treatment of brain diseases.
脑内炎症是多种脑部疾病的一个显著特征。炎症过程在这些病症中的复杂作用表明，神经炎症可能是一个有价值的治疗靶点。虽然已经确定了几种有前途的抗炎药物，但它们在脑部疾病中的临床应用常常受到无法穿过血脑屏障（BBB）并在病理部位达到治疗有效浓度的限制。这一限制突出表明，迫切需要设计有效的穿透 BBB 的药物输送系统，以针对大脑炎症。本综述批判性地研究了过去五年中在旨在减轻阿尔茨海默病和缺血性中风（这两种是全球导致死亡和残疾的主要原因）中脑炎症的药物输送策略方面的最新进展。此外，我们还解决了该领域的关键挑战，为针对脑部疾病中神经炎症的治疗提供了未来的方向。
